Latest From Phil Greenfield
The UK Competition and Markets Authority has concerns over the impact on the market for ankle replacements that would result from Stryker's planned $4bn acquisition of Wright Medical.
Chembio’s stock opened down 60% the day after the FDA’s decision to revoke its EUA for the first US rapid test for antibodies to SARS-CoV-2.
While the main role of SARS-CoV-2 antibody testing is currently limited to determining exposure to the virus in populations, the scientific community is working hard to define the neutralizing properties of the antibodies detected, and the duration of the immune response. As a result, antibody testing could be here to stay for the long term for monitoring populations, testing vaccines and selecting patients for trials of a variety of new therapies to treat numerous conditions.
Siemens Healthineers Adds Muscle To Global Antibody Testing Effort, In Talks With Vaccine Developers
The company now has US emergency use designation for its new SARS-CoV-2 test, which can run on its global installed base of 20,000 analyzers at a current capacity of 50 million tests per month.
The test, made by Fujirebio, will help Japan to reach its 400,000-per-week COVID-19 test target.
The company says the serology test has a specificity of 99.8% and sensitivity of 100%